Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: Lymphangioleiomyomatosis is a rare disease occurring almost exclusively in women. Diagnosis often requires surgical biopsy and the clinical course varies between patients with no predictors of progression. We evaluated recent diagnostic guidelines, clinical features and serum biomarkers as diagnostic and prognostic tools. METHODS: Serum vascular endothelial growth factor-D (VEGF-D), angiotensin converting enzyme (ACE), matrix metalloproteinases (MMP) -2 and -9, clinical phenotype, thoracic and abdominal computerised tomography, lung function and quality of life were examined in a cohort of 58 patients. 32 healthy female controls had serum biomarkers measured. RESULTS: Serum VEGF-D, ACE and total MMP-2 levels were elevated in patients. VEGF-D was the strongest discriminator between patients and controls (median = 1174 vs. 332 pg/ml p 

Original publication

DOI

10.1186/1465-9921-13-34

Type

Journal

Respir Res

Publication Date

18/04/2012

Volume

13

Keywords

Adult, Biomarkers, Cohort Studies, Female, Humans, Lymphangioleiomyomatosis, Matrix Metalloproteinase 2, Matrix Metalloproteinase 9, Middle Aged, Peptidyl-Dipeptidase A, Practice Guidelines as Topic, Respiratory Function Tests, Vascular Endothelial Growth Factor D, Young Adult